176 related articles for article (PubMed ID: 28970470)
1. NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia.
Märklin M; Heitmann JS; Fuchs AR; Truckenmüller FM; Gutknecht M; Bugl S; Saur SJ; Lazarus J; Kohlhofer U; Quintanilla-Martinez L; Rammensee HG; Salih HR; Kopp HG; Haap M; Kirschniak A; Kanz L; Rao A; Wirths S; Müller MR
Nat Commun; 2017 Oct; 8(1):755. PubMed ID: 28970470
[TBL] [Abstract][Full Text] [Related]
2. Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia.
Märklin M; Fuchs AR; Tandler C; Heitmann JS; Salih HR; Kauer J; Quintanilla-Martinez L; Wirths S; Kopp HG; Müller MR
Front Immunol; 2020; 11():1995. PubMed ID: 32983140
[TBL] [Abstract][Full Text] [Related]
3. A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia.
Fuchs AR; Märklin M; Heitmann JS; Futterknecht S; Haap M; Wirths S; Kopp HG; Hinterleitner C; Dörfel D; Müller MR
J Vis Exp; 2018 Dec; (142):. PubMed ID: 30582586
[TBL] [Abstract][Full Text] [Related]
4. Loss of NFAT2 expression results in the acceleration of clonal evolution in chronic lymphocytic leukemia.
Müller DJ; Wirths S; Fuchs AR; Märklin M; Heitmann JS; Sturm M; Haap M; Kirschniak A; Sasaki Y; Kanz L; Kopp HG; Müller MR
J Leukoc Biol; 2019 Mar; 105(3):531-538. PubMed ID: 30556925
[TBL] [Abstract][Full Text] [Related]
5. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy.
Muzio M; Apollonio B; Scielzo C; Frenquelli M; Vandoni I; Boussiotis V; Caligaris-Cappio F; Ghia P
Blood; 2008 Jul; 112(1):188-95. PubMed ID: 18292287
[TBL] [Abstract][Full Text] [Related]
6. CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation.
Garaud S; Morva A; Lemoine S; Hillion S; Bordron A; Pers JO; Berthou C; Mageed RA; Renaudineau Y; Youinou P
J Immunol; 2011 Apr; 186(8):4835-44. PubMed ID: 21398617
[TBL] [Abstract][Full Text] [Related]
7. Is the c-Cbl proto-oncogene involved in chronic lymphocytic leukemia?
Mankaï A; Eveillard JR; Buhé V; Le Ster K; Loisel S; Ghedira I; Youinou P; Berthou C; Bordron A
Ann N Y Acad Sci; 2007 Jun; 1107():193-205. PubMed ID: 17804547
[TBL] [Abstract][Full Text] [Related]
8. LCK is an important mediator of B-cell receptor signaling in chronic lymphocytic leukemia cells.
Talab F; Allen JC; Thompson V; Lin K; Slupsky JR
Mol Cancer Res; 2013 May; 11(5):541-54. PubMed ID: 23505068
[TBL] [Abstract][Full Text] [Related]
9. Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction.
Jeon MS; Atfield A; Venuprasad K; Krawczyk C; Sarao R; Elly C; Yang C; Arya S; Bachmaier K; Su L; Bouchard D; Jones R; Gronski M; Ohashi P; Wada T; Bloom D; Fathman CG; Liu YC; Penninger JM
Immunity; 2004 Aug; 21(2):167-77. PubMed ID: 15308098
[TBL] [Abstract][Full Text] [Related]
10. Dysregulation of anergy-related factors involved in regulatory T cells defects in Systemic Lupus Erythematosus patients: Rapamycin and Vitamin D efficacy in restoring regulatory T cells.
Banica LM; Besliu AN; Pistol GC; Stavaru C; Vlad V; Predeteanu D; Ionescu R; Stefanescu M; Matache C
Int J Rheum Dis; 2016 Dec; 19(12):1294-1303. PubMed ID: 25351606
[TBL] [Abstract][Full Text] [Related]
11. B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities.
Falisi E; Novella E; Visco C; Guercini N; Maura F; Giaretta I; Pomponi F; Nichele I; Finotto S; Montaldi A; Neri A; Rodeghiero F
Hematol Oncol; 2014 Mar; 32(1):22-30. PubMed ID: 23861036
[TBL] [Abstract][Full Text] [Related]
12. Reciprocal NFAT1 and NFAT2 nuclear localization in CD8+ anergic T cells is regulated by suboptimal calcium signaling.
Srinivasan M; Frauwirth KA
J Immunol; 2007 Sep; 179(6):3734-41. PubMed ID: 17785810
[TBL] [Abstract][Full Text] [Related]
13. Anergic CD4+ T cells form mature immunological synapses with enhanced accumulation of c-Cbl and Cbl-b.
Doherty M; Osborne DG; Browning DL; Parker DC; Wetzel SA
J Immunol; 2010 Apr; 184(7):3598-608. PubMed ID: 20207996
[TBL] [Abstract][Full Text] [Related]
14. Involvement of NFAT1 in B cell self-tolerance.
Barrington RA; Borde M; Rao A; Carroll MC
J Immunol; 2006 Aug; 177(3):1510-5. PubMed ID: 16849457
[TBL] [Abstract][Full Text] [Related]
15. The biological and clinical relationship between CD5+23+ monoclonal B-cell lymphocytosis and chronic lymphocytic leukaemia.
Rawstron AC; Bennett F; Hillmen P
Br J Haematol; 2007 Dec; 139(5):724-9. PubMed ID: 18021087
[TBL] [Abstract][Full Text] [Related]
16. IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution.
Mao Z; Quintanilla-Martinez L; Raffeld M; Richter M; Krugmann J; Burek C; Hartmann E; Rudiger T; Jaffe ES; Müller-Hermelink HK; Ott G; Fend F; Rosenwald A
Am J Surg Pathol; 2007 Oct; 31(10):1605-14. PubMed ID: 17895764
[TBL] [Abstract][Full Text] [Related]
17. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor.
Rogers KA; Huang Y; Ruppert AS; Salem G; Stephens DM; Heerema NA; Andritsos LA; Awan FT; Byrd JC; Flynn JM; Maddocks KJ; Jones JA
Br J Haematol; 2018 Jan; 180(2):259-266. PubMed ID: 29193006
[TBL] [Abstract][Full Text] [Related]
18. Immature dendritic cells convert anergic nonregulatory T cells into Foxp3- IL-10+ regulatory T cells by engaging CD28 and CTLA-4.
Pletinckx K; Vaeth M; Schneider T; Beyersdorf N; Hünig T; Berberich-Siebelt F; Lutz MB
Eur J Immunol; 2015 Feb; 45(2):480-91. PubMed ID: 25382658
[TBL] [Abstract][Full Text] [Related]
19. Egr-2 and Egr-3 are negative regulators of T cell activation.
Safford M; Collins S; Lutz MA; Allen A; Huang CT; Kowalski J; Blackford A; Horton MR; Drake C; Schwartz RH; Powell JD
Nat Immunol; 2005 May; 6(5):472-80. PubMed ID: 15834410
[TBL] [Abstract][Full Text] [Related]
20. Divergent expression of cyclin-dependent kinase inhibitors (CKI) and p14ARF/p16 beta in non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
Pabst T; Peters UR; Tinguely M; Schwaller J; Tschan M; Aebi S; Vonlanthen S; Borisch B; Betticher DC; Zimmermann A; Tobler A; Fey MF
Leuk Lymphoma; 2000 May; 37(5-6):639-48. PubMed ID: 11042528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
